loader image
Sunday, December 21, 2025
79 F
McAllen
- Advertisement -

COVID-19 Booster for Children Ages 5-11 in Laredo

Translate to Spanish or other 102 languages!

 The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. Image for illustration purposes
The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. Image for illustration purposes

Mega Doctor News

- Advertisement -

LAREDO, Texas – The U.S. Food and Drug Administration authorized a single booster of the Pfizer-BioNTech COVID-19 vaccine for individuals 5 through 11 years of age at least five months after completion of their primary series. 

Pfizer’s clinical trial showed that a booster dose of the Pfizer-BioNTech COVID-19 Vaccine prompted a robust immune response in this age group, generating neutralizing antibodies against the SARS-CoV-2 virus regardless of prior SARS-CoV-2 infection. The actions taken by the FDA would make all Americans 5 and older eligible for a booster shot.

“FDA/CDC pediatric booster approval ensures a higher level of COVID-19 protection amongst children over the summer and when returning to school in the fall,” says Dr. Richard Chamberlain, Health Director, “We continue to urge our community to get vaccinated; vaccines work, vaccines are safe, and vaccines save lives. Stay up-to-date with your vaccines”.

- Advertisement -

The City of Laredo Health Department will provide COVID-19 boosters shots to children 5-11 years of age starting Friday, May 20, 2022. Vaccines will be available at the City of Laredo Health Department Clinic located at 2600 Cedar Ave. or across the city of Laredo via our Mobile Health Clinic

For more information or updates, please follow our social media channels at @LaredoHealth or call (956) 236-8311.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.
- Advertisement -
×